Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer (Journal article)

Aravantinos, G./ Bafaloukos, D./ Fountzilas, G./ Christodoulou, C./ Papadimitriou, C./ Pavlidis, N./ Kalofonos, H. P./ Gogas, H./ Kosmidis, P./ Dimopoulos, M. A.


BACKGROUND: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. PATIENTS AND METHODS: Treatment consisted of vinorelbine 25 mg/m(2) as a 20-min i.v. infusion (days 1 and 8), and docetaxel 70 mg/m(2), as a 1-h i.v. infusion (day 8). Granulocyte colony-stimulating factor support was administered prophylactically on days 12-16. Treatment was repeated every 21 days. RESULTS: Forty-six patients were enrolled. The median number of previous chemotherapeutic regimens was one (range 1-3) with a median treatment-free interval of 4.3 months. Four chemotherapy cycles per patient were administered. Almost 75% of the planned doses for both drugs were given. Forty-one patients are evaluable for response. Three patients (6.5% of all patients; 7.3% of evaluable patients) achieved complete response and eight (17.4% and 19.5%, respectively) a partial response to chemotherapy, leading to overall response rates of 23.9% and 26.8%, respectively. Another 34.8% (39.0%) had stable disease. At a median follow-up of 30 months, the median disease-free survival was 13 months, relapse-free survival was 5 months, time to progression was 4.5 months, and overall survival was 9.3 months. Severe toxicities included leukopenia (31%), neutropenia (35%) and febrile neutropenia (20%). CONCLUSIONS: The combination of docetaxel/vinorelbine is an effective regimen with manageable toxicity for the treatment of platinum-resistant, paclitaxel-pretreated ovarian cancer.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Antineoplastic Agents/pharmacology,Antineoplastic Agents, Phytogenic/pharmacology,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use,Cisplatin/pharmacology,Disease Progression,Disease-Free Survival,Drug Resistance, Neoplasm,Female,Granulocyte Colony-Stimulating Factor/administration & dosage,Humans,Leukopenia/chemically induced,Middle Aged,Neoplasm Recurrence, Local/*drug therapy/pathology,Neutropenia/chemically induced,Ovarian Neoplasms/*drug therapy/pathology,Paclitaxel/administration & dosage/*analogs & derivatives/pharmacology,Prospective Studies,*Taxoids,Treatment Outcome,Vinblastine/administration & dosage/*analogs & derivatives
URI: http://olympias.lib.uoi.gr/jspui/handle/123456789/19319
ISSN: 0923-7534
Link: http://www.ncbi.nlm.nih.gov/pubmed/12853352
http://annonc.oxfordjournals.org/content/14/7/1094.full.pdf
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Aravantinos-2003-Phase II study of do.pdf79.99 kBAdobe PDFView/Open    Request a copy



 Please use this identifier to cite or link to this item:
http://olympias.lib.uoi.gr/jspui/handle/123456789/19319
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.